The manufacturers Biontech and Pfizer want to deliver an additional four million doses of CoV vaccine to the European Union in the next two weeks. The additional package was negotiated so that the EU states could vaccinate specifically in CoV hotspots and slow the spread of the dreaded virus variants, said EU Commission chief Ursula von der Leyen today in Brussels.
The Commission hopes that targeted vaccinations in hotspots will make stricter controls at the EU’s internal borders unnecessary. „By being used specifically where they are most needed, especially in the border regions, these cans will help to secure or restore the freedom of movement of goods and people,“ says von der Leyen. „These are crucial for the functioning of health systems and the internal market.“
The EU Commission expects a total of around 100 million doses of the three vaccines from Biontech and Pfizer, Moderna and AstraZeneca, which have so far been approved in the EU, for the first quarter through the end of March. Biontech and Pfizer were originally supposed to deliver 62 million doses of this total, now 66 million.
